首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial
【2h】

Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial

机译:青光眼和眼高压试验(LiGHT)的Laser-1st和Drops-1st的统计分析计划:一项多中心随机对照试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe LiGHT trial (Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial) is a multicentre randomised controlled trial of two treatment pathways for patients who are newly diagnosed with open-angle glaucoma (OAG) and ocular hypertension (OHT). The main hypothesis for the trial is that lowering intraocular pressure (IOP) with selective laser trabeculoplasty (SLT) as the primary treatment (‘Laser-1st’) leads to a better health-related quality of life than for those started on IOP-lowering drops as their primary treatment (‘Medicine-1st’) and that this is associated with reduced costs and improved tolerability of treatment. This paper describes the statistical analysis plan for the study.
机译:背景LiGHT试验(青光眼和高眼压试验的Laser-1st与Drops-1st)是一项多中心随机对照试验,针对新诊断为开角型青光眼(OAG)和高眼压(OHT)的患者采用两种治疗途径。该试验的主要假设是,以选择性激光小梁成形术(SLT)作为主要治疗方法(“ Laser-1st”)降低眼内压(IOP)会导致与健康相关的生活质量优于降低IOP的患者作为主要治疗药物('Medicine-1st')下降,这与降低成本和提高治疗耐受性有关。本文介绍了这项研究的统计分析计划。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号